Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

Myeloproliferative neoplasms (MPN) that have evolved into accelerated or blast phase disease (MPN-AP/BP) have poor outcomes with limited treatment options and therefore represent an urgent unmet need. We have previously demonstrated in a multicenter, phase 1 trial conducted through the Myeloprolifer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Mascarenhas, John O., Rampal, Raajit K., Kosiorek, Heidi E., Bhave, Rupali, Hexner, Elizabeth, Wang, Eunice S., Gerds, Aaron, Abboud, Camille N., Kremyanskaya, Marina, Berenzon, Dimitry, Odenike, Olatoyosi, Farnoud, Noushin, Krishnan, Aishwarya, Weinberg, Rona Singer, McGovern, Erin, Salama, Mohamed E., Najfeld, Vesna, Medina-Martinez, Juan S., Arango Ossa, Juan E., Levine, Max F., Zhou, Yangyu, Sandy, Lonette, Heaney, Mark L., Levine, Ross L., Mesa, Ruben A., Dueck, Amylou C., Hoffman, Ronald
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594401/
https://ncbi.nlm.nih.gov/pubmed/33104796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002119
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados